Erste Group Bank Issues Pessimistic Outlook for MRK Earnings

Merck & Co., Inc. (NYSE:MRK) – Analysts at Erste Group Bank cut their FY2026 earnings estimates for Merck & Co., Inc. in a research report issued on Wednesday, October 21st. Erste Group Bank analyst H. Engel now anticipates that the company will post earnings of $2.63 per share for the year, down from their prior estimate of $2.73. The consensus estimate for Merck & Co., Inc.’s current full-year earnings is $2.66 per share. Erste Group Bank also issued estimates for Merck & Co., Inc.’s FY2027 earnings at $9.38 EPS.

Several other equities analysts also recently issued reports on MRK. Jefferies Financial Group boosted their price objective on Merck & Co., Inc. from $152.00 to $175.00 and gave the stock a “buy” rating in a research report on Thursday, August 20th. Rothschild & Co Redburn increased their price target on Merck & Co., Inc. from $140.00 to $145.00 and gave the stock a “buy” rating in a research note on Monday, July 6th. Guggenheim raised their price target on Merck & Co., Inc. from $146.00 to $170.00 and gave the company a “buy” rating in a report on Tuesday, September 8th. JPMorgan Chase & Co. lifted their price objective on shares of Merck & Co., Inc. from $150.00 to $165.00 and gave the company an “overweight” rating in a research note on Monday, October 5th. Finally, The Goldman Sachs Group upped their price objective on shares of Merck & Co., Inc. from $140.00 to $160.00 and gave the stock a “buy” rating in a report on Friday, August 21st. Seventeen investment analysts have rated the stock with a Buy rating, nine have issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, Merck & Co., Inc. currently has an average rating of “Moderate Buy” and an average target price of $151.92.

Merck & Co., Inc. Trading Down 1.7%

NYSE MRK opened at $147.40 on Friday. The company has a debt-to-equity ratio of 1.22, a quick ratio of 1.10 and a current ratio of 1.32. The company has a 50-day simple moving average of $146.79 and a 200-day simple moving average of $130.07. Merck & Co., Inc. has a one year low of $82.01 and a one year high of $156.92. The firm has a market capitalization of $363.67 billion, a PE ratio of 117.92, a price-to-earnings-growth ratio of 6.92 and a beta of 0.21.

Merck & Co., Inc. (NYSE:MRK) last posted its quarterly earnings results on Tuesday, August 4th. The company reported ($0.13) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.26) by $0.13. The firm had revenue of $16.61 billion for the quarter, compared to analysts’ expectations of $16.37 billion. Merck & Co., Inc. had a net margin of 4.77% and a return on equity of 16.73%. The firm’s quarterly revenue was up 5.1% on a year-over-year basis. During the same period in the prior year, the company posted $2.13 earnings per share. Merck & Co., Inc. has set its FY 2026 guidance at 2.660-2.760 EPS.

Institutional Investors Weigh In On Merck & Co., Inc.

Several institutional investors have recently modified their holdings of the business. BlackRock Inc. raised its stake in Merck & Co., Inc. by 0.5% during the 2nd quarter. BlackRock Inc. now owns 226,999,837 shares of the company’s stock worth $29,169,479,000 after buying an additional 1,073,507 shares during the period. State Street Corp increased its position in shares of Merck & Co., Inc. by 0.9% in the second quarter. State Street Corp now owns 120,413,256 shares of the company’s stock valued at $15,573,754,000 after acquiring an additional 1,087,583 shares during the last quarter. Wellington Management Group LLP boosted its position in Merck & Co., Inc. by 2.3% during the second quarter. Wellington Management Group LLP now owns 86,249,283 shares of the company’s stock valued at $11,083,033,000 after purchasing an additional 1,934,312 shares during the last quarter. Bank of America Corp DE grew its stake in Merck & Co., Inc. by 10.5% in the first quarter. Bank of America Corp DE now owns 30,774,221 shares of the company’s stock valued at $3,701,831,000 after purchasing an additional 2,919,780 shares in the last quarter. Finally, Dimensional Fund Advisors LP raised its position in Merck & Co., Inc. by 23.8% during the first quarter. Dimensional Fund Advisors LP now owns 15,456,039 shares of the company’s stock worth $1,858,938,000 after acquiring an additional 2,969,856 shares in the last quarter. Institutional investors and hedge funds own 76.07% of the company’s stock.

Insiders Place Their Bets

In other Merck & Co., Inc. news, EVP Chirfi Guindo sold 10,000 shares of the stock in a transaction on Thursday, August 13th. The shares were sold at an average price of $135.00, for a total value of $1,350,000.00. Following the completion of the sale, the executive vice president directly owned 36,613 shares of the company’s stock, valued at $4,942,755. This represents a 21.45% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, EVP Jennifer Zachary sold 80,315 shares of the firm’s stock in a transaction dated Wednesday, August 12th. The stock was sold at an average price of $133.46, for a total transaction of $10,718,839.90. Following the transaction, the executive vice president directly owned 45,509 shares of the company’s stock, valued at $6,073,631.14. The trade was a 63.83% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 228,238 shares of company stock worth $29,977,783 in the last 90 days. 0.17% of the stock is owned by corporate insiders.

Merck & Co., Inc. Dividend Announcement

The firm also recently disclosed a quarterly dividend, which was paid on Wednesday, October 7th. Investors of record on Tuesday, September 15th were given a dividend of $0.85 per share. This represents a $3.40 annualized dividend and a yield of 2.3%. The ex-dividend date of this dividend was Tuesday, September 15th. Merck & Co., Inc.’s dividend payout ratio (DPR) is presently 272.00%.

Trending Headlines about Merck & Co., Inc.

Here are the key news stories impacting Merck & Co., Inc. this week:

• Positive Sentiment: The European Commission approved KEYTRUDA plus Padcev as perioperative treatment for adults with resectable muscle-invasive bladder cancer. The label applies regardless of cisplatin eligibility, broadening the addressable patient population and supporting future KEYTRUDA revenue. This is also the EU’s first approval of a PD-1 inhibitor combined with an antibody-drug conjugate in this setting. European Commission Approves KEYTRUDA Plus Padcev
• Positive Sentiment: Merck and Moderna reported that the Phase 3 INTerpath-001 trial of personalized cancer vaccine intismeran plus KEYTRUDA produced positive recurrence-free and distant metastasis-free survival results in melanoma. The combination reduced the risk of recurrence or death by 42%, strengthening the long-term potential of Merck’s oncology pipeline. Moderna and Merck Cancer Vaccine Results
• Neutral Sentiment: Trading in Merck call options was unusually active, with investors purchasing approximately 37,444 contracts—about 40% above average volume. This may indicate speculative bullish interest, but options activity does not necessarily signal a change in fundamentals.
• Negative Sentiment: Despite the strong melanoma results, the data appeared to leak ahead of the formal presentation, prompting a sell-the-news reaction. Investors may have already priced in favorable results, while the initial reports raised questions about how compelling the efficacy profile was relative to expectations. Merck declined alongside Moderna, although Moderna experienced the sharper reaction. Moderna Shares Plunge on Cancer Vaccine Data Leak
• Negative Sentiment: Analysts expect Merck’s third-quarter earnings to decline, creating an additional overhang ahead of the company’s report. With a high reported price-to-earnings ratio, the stock may be particularly sensitive to disappointing earnings or guidance. Merck Q3 Earnings Preview

About Merck & Co., Inc.

Merck & Co, Inc is a global healthcare company that develops, manufactures and markets prescription medicines, vaccines and animal-health products. Its pharmaceutical business focuses on oncology, infectious diseases, cardiology, immunology and other areas of significant medical need. The company serves patients, healthcare providers and institutions in markets worldwide.

Merck’s principal products include Keytruda, an immunotherapy used to treat a range of cancers; Gardasil and Gardasil 9, vaccines that help protect against human papillomavirus; and Januvia and Janumet, medicines used to manage type 2 diabetes.